Updated Jul 16, 2026
O'NEIL PATRICK R. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $16.03M.

Patrick R. O'Neil serves as the Executive Vice President, Chief Legal Officer, and General Counsel at Ionis Pharmaceuticals, a leader in antisense technology for drug development. He has been involved in the company through various SEC filings, indicating a significant role in its legal and corporate governance.
| Role | EVP CLO & General Counsel |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 3.1K | $80.00 | $246K |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 10.1K | $75.25 | $764K |
| 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | J — Other acquisition / disposition | 376 | $48.87 | $18K |
| 2026-02-03 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 6.2K | $83.53 | $516K |
| 2026-02-03 | IONS | IONIS PHARMACEUTICALS INC | A — Grant or award | 12.0K | $0.00 | |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 9.2K | $75.84 | $697K |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 21.5K | $0.00 | |
| 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 3.2K | $69.27 | $224K |
| 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 10.2K | $69.89 | $713K |
| 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 10.2K | $52.87 | $539K |
| 2025-10-02 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 34.5K | $67.69 | $2.33M |
| 2025-10-02 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 34.5K | $60.89 | $2.10M |
| 2025-10-02 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 30.2K | $67.69 | $2.04M |
| 2025-10-02 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 30.2K | $56.78 | $1.71M |
| 2025-09-29 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 14.8K | $64.68 | $959K |
| 2025-09-29 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 14.8K | $56.78 | $842K |
| 2025-09-29 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 10.5K | $64.54 | $676K |
| 2025-09-29 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 10.5K | $56.78 | $595K |
| 2025-09-12 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 1.7K | $64.58 | $110K |
| 2025-09-12 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 1.7K | $56.78 | $97K |
Patrick R. O'Neil serves as the Executive Vice President, Chief Legal Officer, and General Counsel at Ionis Pharmaceuticals, a leader in antisense technology for drug development. He has been involved in the company through various SEC filings, indicating a significant role in its legal and corporate governance.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($16.03M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live O'NEIL PATRICK R. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.